… To the best of our knowledge, this is the first trial to provide information about the efficacy
and safety of first-line treatment with erlotinib in a controlled population of PS 2patients with …

… -study was also negative regarding Erlotinib as first-line treatment in NSCLC: In this study,
treatment-naïve NSCLC-patients either received Erlotinib daily or conventional chemotherapy …

… All 42 patients showed PD after having received gefitinib or erlotinib for a year prior to this
study… The median PFS was 31 months in the gefitinib and 24 months in the erlotinib group. No …

… Despite the limitations of our efficacy analysis, the current study demonstrates an important
first step in evaluating erlotinib as a potential therapy for high-risk patients after salvage …

… of studying the efficacy of first-line erlotinib therapy in patients with activating EGFR
mutations. The concept of treatment beyond RECIST 1.1 progression and the use of plasma-based …

… an arm evaluating navitoclax combined with erlotinib, which included a dose escalation …
Patients with documented cancers for whom erlotinib therapy was appropriate received erlotinib …

… Assuming that erlotinib comprises 30% of second-line … are $382,418 with erlotinib and
$380,968 without erlotinib (difference… This budget impact model does not consider efficacy beyond …

… In the present trial, the goal was to see whether sorafenib could improve the efficacy already
achieved with erlotinib. Preclinical and phase I data provide rationale for using these drugs …

… Erlotinib is currently approved for second-line therapy and … will probably lead to the
approval of erlotinib for the first-line … chemotherapy provided that the efficacy of oral therapy is …

… was efficacious in both the intent-to-treat and stable disease populations. Patient … analysis
of erlotinib versus pemetrexed were to be performed, the comparable efficacy of erlotinib and …